Bibliography
- Saxena U. Alzheimer's disease amyloid hypothesis at cross roads: where do we go from here? Expert Opin Ther Targets 2010;14:1273-7
- Saxena U. Bioenergetics breakdown in Alzheimer's disease: targets for new therapies. Int J Physiol Pathophysiol Pharmacol 2011;3:133-9
- Mosconi L, Pupi A, De Leon MJ. Brain glucose hypometabolism and oxidative stress in preclinical Alzheimer's disease. Ann NY Acad Sci 2008;1147:180-95
- Mosconi L, Mistur R, Switalski R, FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer's disease. Eur J Nucl Med Mol Imaging 2009;36:811-22
- Mosconi L. Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD. Eur J Nucl Med Mol Imaging 2005;32:486-510
- Devanand DP, Mikhno A, Pelton GH, Pittsburgh compound B (11C-PIB) and fluorodeoxyglucose (18F-FDG) PET in patients with Alzheimer disease, mild cognitive impairment, and healthy controls. J Geriatr Psychiatry Neurol 2010;23:185-98
- Rostomian AH, Madison C, Rabinovici GD, Jagust WJ. Early 11C-PIB frames and 18-FDG PET measures are comparable: A study validated in a cohort of AD and FTLD patients J Nucl Med. 2011;52:173-9
- Cookson MR, Bandmann O. Parkinson's disease: insights from pathways. Hum Mol Genet 2010;19(R1):R21-7
- Zheng B, Liao Z, Locascio JJ, Global PD Gene Expression (GPEX) consortium. PGC-1alpha, a potential therapeutic target for early intervention in Parkinson's disease. Sci Transl Med 2010;2:52-73
- Ebrahim AS, Ko LW, Yen SH. Reduced expression of peroxisome-proliferator activated receptor gamma coactivator-1alpha enhances alpha-synuclein oligomerization and down regulates AKT/GSK3beta signaling pathway in human neuronal cells that inducibly express alpha-synuclein. Neurosci Lett 2010;473:120-5
- Pappata S, Santangelo G, Aarsland D, Mild cognitive impairment in drug-naive patients with PD is associated with cerebral hypometabolism. Neurology 2011;77:1357-62
- Bohnen NI, Koeppe RA, Minoshima S, Cerebral glucose metabolic features of Parkinson disease and incident dementia: longitudinal study. J Nucl Med 2011;52:848-55
- Zuccato C, Valenza M, Cattaneo E. Molecular mechanisms and potential therapeutical targets in Huntington's disease. Physiol Rev 2010;90:905-81
- Damiano M, Galvan L, Deglon N, Brouillet E. Mitochondria in Huntington's disease. Biochim Biophys Acta 2010;1802:52-61
- Kuwert T, Lange HW, Boecker H, Striatal glucose consumption in chorea-free subjects at risk of Huntington's disease. J Neurol 1993;241:31-6
- Grafton ST, Mazziotta JC, Pahl JJ, Serial changes of cerebral glucose metabolism and caudate size in persons at risk for Huntington's disease. Arch Neurol 1992;49:1161-7
- Jenkins BG, Koroshetz WJ, Beal MF, Rosen BR. Evidence for impairment of energy metabolism in vivo in Huntington's disease using localized 1H NMR spectroscopy. Neurology 1993;43:2689-95